Fig. 5: SARS-CoV-2–specific humoral responses in PLWH receiving the original–BA.4/5 bivalent booster.
From: Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV
RBD-binding antibodies – expressed as area under the curve (AUC) – against WT and BA.4/5 virus in the entire cohort of PLWH (a) and in PLWH stratified according to previous SARS-CoV-2 infection (b). RBD-blocking antibodies – expressed as percentage (%) of inhibition of RBD-ACE2 binding – against WT and BA.4/5 virus in the entire cohort of PLWH (c) and in PLWH stratified according to previous SARS-CoV-2 infection (d). Green/orange circles (scatter plots): individual values; black bars (scatter plots): median values; green/orange boxes (scatter plots): interquartile ranges; green/orange diamonds and triangles (trajectory plots): median values; green/orange error bars (trajectory plots): interquartile ranges; statistical analyses in scatter plots: Kruskall–Wallis test with Dunn’s multiple comparisons test (comparison between time-points; P values < 0.05 showed in green or orange above solid lines) and Wilcoxon test (comparison between WT- and BA.4/5-reactive T cells; P values < 0.05 showed in black above dashed lines); statistical analyses in trajectory plots: Mann–Whitney test (comparison between PLWH with no SARS-CoV-2 infection and PLWH with previous SARS-CoV-2 infection); T0 (day of booster administration): n = 29; T1 (1 month after booster administration): n = 29; T2 (4–9 months after booster administration): n = 24. e Correlation between RBD-binding and RBD-blocking antibodies. Green/orange circles: individual values; solid black line: simple linear regression line; green/orange shadows: 95% confidence bands; statistical analysis: Spearman’s correlation test (r and P value reported above the plot).
